Sint Maarten (Dutch part) vs United States Virgin Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology

Sint Maarten (Dutch part)
0.2%
in 2024
United States Virgin Islands
0.2%
in 2024
Sint Maarten (Dutch part) rank
98th
United States Virgin Islands rank
98th

Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time

  • Sint Maarten (Dutch part)
  • United States Virgin Islands
00.10.20.30.4201520192024

How they compare

Sint Maarten (Dutch part) currently reports 0.2% against 0.2% in United States Virgin Islands, a difference of 0.0%.

Across all 10 years both countries report, United States Virgin Islands has been ahead every year.

Sint Maarten (Dutch part) ranks 98th and United States Virgin Islands ranks 98th of 246 countries.

Head to head by decade

Decade Sint Maarten (Dutch part) United States Virgin Islands Difference Ahead
2010s 0.3% 0.3% 0.0%
2020s 0.2% 0.2% 0.0%

Averages of every year both report within each decade.

Frequently asked questions

Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Sint Maarten (Dutch part) or United States Virgin Islands?
Sint Maarten (Dutch part), at 0.2% against 0.2% in United States Virgin Islands as of 2024.
What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Sint Maarten (Dutch part) and United States Virgin Islands?
0.0%, with Sint Maarten (Dutch part) ahead.
How many years of comparable data are there for Sint Maarten (Dutch part) and United States Virgin Islands?
10 years are reported by both, from 2015 to 2024.
How do Sint Maarten (Dutch part) and United States Virgin Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
Sint Maarten (Dutch part) ranks 98th and United States Virgin Islands ranks 98th of 246 countries.
Where does this data come from?
United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Sint Maarten (Dutch part) vs United States Virgin Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology. Statizoid, drawing on United Nations Statistics Division, SDG Global Database. Retrieved 09 September 2026, from https://development-goals.statizoid.com/compare/prevalence-of-hepatitis-b-surface-antigen-hbsag-2026-methodology-percent/sint-maarten-dutch-part/virgin-islands-u-s/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under UN SDG Global Database (open, attribution requested); please keep the attribution.

<a href="https://development-goals.statizoid.com/compare/prevalence-of-hepatitis-b-surface-antigen-hbsag-2026-methodology-percent/sint-maarten-dutch-part/virgin-islands-u-s/">Sint Maarten (Dutch part) vs United States Virgin Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology</a> — Statizoid

About this data

Indicator
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%)
Unit
%
Source
United Nations Statistics Division, SDG Global Database
Licence
UN SDG Global Database (open, attribution requested)
Coverage
250 places, 2,500 data points, 2015–2024
Last refreshed